Stockscreener 앱 받기
78.36
0.55%
0.4787
전일 마감가:
$77.88
열려 있는:
$77.4
하루 거래량:
494.12K
Relative Volume:
0.20
시가총액:
$12.22B
수익:
$4.39B
순이익/손실:
$-1.58B
주가수익비율:
-7.8673
EPS:
-9.96
순현금흐름:
$546.00M
1주 성능:
+1.41%
1개월 성능:
+5.60%
6개월 성능:
-49.46%
1년 성능:
-33.60%
1일 변동 폭
$77.08
$79.00
1주일 범위
$75.41
$79.22
52주 변동 폭
$68.70
$156.66
일루미나 Stock (ILMN) Company Profile
명칭
Illumina Inc
전화
(858) 202-4500
주소
5200 ILLUMINA WAY, SAN DIEGO, CA
ILMN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
78.33 | 12.22B | 4.39B | -1.58B | 546.00M | -9.96 |
|
TMO
Thermo Fisher Scientific Inc
|
422.02 | 159.05B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
198.60 | 140.21B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
475.40 | 35.17B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
108.59 | 30.47B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
153.37 | 26.47B | 15.41B | 1.37B | 2.11B | 7.50 |
일루미나 Stock (ILMN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-04 | 재확인 | Citigroup | Neutral |
| 2025-02-28 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-02-10 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-02-07 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-11-12 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-10-17 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-08-28 | 업그레이드 | Argus | Hold → Buy |
| 2024-08-16 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2024-08-14 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-07-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-01-16 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-14 | 개시 | Stephens | Overweight |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-12-11 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-11-10 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | 개시 | Bernstein | Underperform |
| 2023-07-05 | 재개 | JP Morgan | Neutral |
| 2023-01-25 | 다운그레이드 | Argus | Buy → Hold |
| 2023-01-05 | 개시 | Scotiabank | Sector Perform |
| 2022-12-12 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2022-10-04 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Neutral |
| 2022-07-13 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2022-01-18 | 업그레이드 | Stifel | Hold → Buy |
| 2022-01-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-01-07 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-08-19 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-03-31 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | 개시 | Barclays | Underweight |
| 2020-12-22 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-10-13 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-09-30 | 개시 | Atlantic Equities | Overweight |
| 2020-09-29 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-09-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-09-21 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-08-07 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2020-08-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-04-24 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-04-21 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | 개시 | Wells Fargo | Underweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-10-25 | 개시 | Guggenheim | Buy |
모두보기
일루미나 주식(ILMN)의 최신 뉴스
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Illumina, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2024ILMN - ACCESS Newswire
Case study: Professor Sir Shankar Balasubramanian FRS - Royal Society
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Illumina, Inc.(ILMN) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Illumina, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 14, 2017ILMN - ACCESS Newswire
Epigenetics Market Is Booming So Rapidly 2025-2032 -Illumina - openPR.com
Illumina (ILMN) and Ovation.io Launch Major Clinical Multiomic D - GuruFocus
Global Molecular Diagnostics Market to Expand at a CAGR of ~9% by 2032 Due to the Rising Demand for Precision Medicine | DelveInsight - GlobeNewswire Inc.
June 13th Options Now Available For Illumina (ILMN) - Nasdaq
Illumina Partners With Ovation.io to Create GLP-1 Dataset for Drug Discovery - marketscreener.com
Illumina (ILMN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Illumina, Ovation.io launching first-of-kind GLP-1 dataset - TipRanks
Illumina and Ovation.io unveil large GLP-1 therapy dataset - Investing.com
Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development - PR Newswire
Even after rising 3.7% this past week, Illumina (NASDAQ:ILMN) shareholders are still down 74% over the past five years - Yahoo Finance
Canaccord Reduces Price Target for Illumina (ILMN) Amid Economic Challenges | ILMN Stock News - GuruFocus
When (ILMN) Moves Investors should Listen - news.stocktradersdaily.com
Press Release Distribution & PR Platform - ACCESS Newswire
Digital Genome Market Set to Witness Significant Growth - openPR.com
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Illumina, Inc. (ILMN) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
The path to precision medicine in Indonesia - Illumina
Computational Biology Market New Product Development & Latest - openPR.com
Genetic Testing Market Generated Opportunities, Future Scope - openPR.com
DNA and RNA Sample Preparation Market Projected To Witness - openPR.com
2024 Illumina Epigenetics Research Contest Winner Investigates Blood Transfusion Off-Target Effects - Illumina
Should You Hold Illumina (ILMN)? - MSN
June 6th Options Now Available For Illumina (ILMN) - Nasdaq
It’s all about accessibility: Developing technical training for the MiSeq i100 Series - Illumina
Veraxa makes a SPAC deal; Illumina discloses layoffs - Endpoints News
Resmed Taps Illumina Exec for Chief Investor Relations Officer Role - Medical Product Outsourcing
Microarray Market Projected To Witness Massive Growth, 2025-2032 | Thermo Fisher Scientific Inc.,Illumina Inc. - openPR.com
DNA Microarray Technology Market: Innovations & Opportunities - openPR.com
Cancer Biopsy Market Detailed In New Research Report 2025 | - openPR.com
Genomic Cancer Testing Market Overall Study Report 2025-2032 | - openPR.com
Thomas Kean Jr purchases shares in Illumina and nVent Electric - Investing.com Australia
Resmed Names Salli Schwartz as Chief Investor Relations Officer - The Manila Times
Illumina, Inc. (ILMN): Among Recent Activist Investor Campaigns - Insider Monkey
Controlling Genes Market Detailed in New Research Report By 2032 - openPR.com
Illumina (ILMN) Receives a Buy from Leerink Partners - The Globe and Mail
Illumina, Tempus AI partner to drive genomic testing beyond cancer - MedTech Dive
Q4 Rundown: Illumina (NASDAQ:ILMN) Vs Other Life Sciences Tools & Services Stocks - Yahoo Finance
일루미나 (ILMN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.10%
0.42%
자본화:
|
볼륨(24시간):